These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 27217070)

  • 21. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.
    Nguyen KD; Tran TN; Nguyen MT; Nguyen HA; Nguyen HA; Vu DH; Nguyen VD; Bagheri H
    J Clin Pharm Ther; 2019 Feb; 44(1):69-77. PubMed ID: 30129156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Signal detection and preventability from Vietnam National pharmacovigilance database.
    Huong PT; Ha TN; Nhu TTQ; Nga NTH; Anh NH; Hoa VD; Binh NQ; Anh NH
    J Clin Pharm Ther; 2022 Dec; 47(12):2014-2019. PubMed ID: 35848069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.
    Tohkin M; Kaniwa N; Saito Y; Sugiyama E; Kurose K; Nishikawa J; Hasegawa R; Aihara M; Matsunaga K; Abe M; Furuya H; Takahashi Y; Ikeda H; Muramatsu M; Ueta M; Sotozono C; Kinoshita S; Ikezawa Z;
    Pharmacogenomics J; 2013 Feb; 13(1):60-9. PubMed ID: 21912425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
    Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
    Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
    Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults.
    Hsu DY; Brieva J; Silverberg NB; Silverberg JI
    J Invest Dermatol; 2016 Jul; 136(7):1387-1397. PubMed ID: 27039263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Lee HY; Pang SM; Thamotharampillai T
    J Am Acad Dermatol; 2008 Aug; 59(2):352-3. PubMed ID: 18638633
    [No Abstract]   [Full Text] [Related]  

  • 29. Recurrence of Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol and piroxicam.
    Xiong H; Liu G; Xiao J; Han Y; Liu T; Wan J; Yang J; Ding J; Dong X
    Eur J Dermatol; 2020 Oct; 30(5):620-621. PubMed ID: 33185537
    [No Abstract]   [Full Text] [Related]  

  • 30. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Harr T; French LE
    Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI
    Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.
    Borrelli EP; Lee EY; Descoteaux AM; Kogut SJ; Caffrey AR
    Epilepsia; 2018 Dec; 59(12):2318-2324. PubMed ID: 30395352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe.
    Génin E; Schumacher M; Roujeau JC; Naldi L; Liss Y; Kazma R; Sekula P; Hovnanian A; Mockenhaupt M
    Orphanet J Rare Dis; 2011 Jul; 6():52. PubMed ID: 21801394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Pham CH; Gillenwater TJ; Nagengast E; McCullough MC; Peng DH; Garner WL
    Burns; 2019 Nov; 45(7):1634-1638. PubMed ID: 31466921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
    Halevy S
    Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience.
    McCullough M; Burg M; Lin E; Peng D; Garner W
    Burns; 2017 Feb; 43(1):200-205. PubMed ID: 27554629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database.
    Lebrun-Vignes B; Guy C; Jean-Pastor MJ; Gras-Champel V; Zenut M;
    Br J Clin Pharmacol; 2018 Feb; 84(2):331-338. PubMed ID: 28963996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases.
    Davis RL; Gallagher MA; Asgari MM; Eide MJ; Margolis DJ; Macy E; Burmester JK; Selvam N; Boscarino JA; Cromwell LF; Feigelson HS; Kuntz JL; Pawloski PA; Penfold RB; Raebel MA; Sridhar G; Wu A; La Grenade LA; Pacanowski MA; Pinheiro SP
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):684-92. PubMed ID: 25914229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.
    Kang HR; Jee YK; Kim YS; Lee CH; Jung JW; Kim SH; Park HW; Chang YS; Jang IJ; Cho SH; Min KU; Kim SH; Lee KW;
    Pharmacogenet Genomics; 2011 May; 21(5):303-7. PubMed ID: 21301380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allopurinol: Clinical Considerations in the Development and Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Other Associated Drug Reactions.
    Dillman KM; Hawkins AM; Ragland AR; Wester GC; Greene DR; Varrassi G; Moore P; Behara R; Ahmadzadeh S; Siddaiah H; Shekoohi S; Kaye AD
    Cureus; 2024 Jul; 16(7):e64654. PubMed ID: 39149682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.